ロード中...
Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis
BACKGROUND: Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is widely described in children. Clinical evidence in adults is limited. The objective of this study was to determine the treatment outcomes of RTX in adults with FSGS and MCD. METHODS:...
保存先:
| 出版年: | BMC Nephrol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7160971/ https://ncbi.nlm.nih.gov/pubmed/32293308 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-020-01797-7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|